53. Combination Anabolic and Antiresorptive Therapy for Osteoporosis

  1. Clifford J. Rosen MD
  1. John P. Bilezikian and
  2. Natalie E. Cusano

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch53

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

Bilezikian, J. P. and Cusano, N. E. (2013) Combination Anabolic and Antiresorptive Therapy for Osteoporosis, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch53

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • anabolic therapy;
  • antiresorptive therapy;
  • osteoporosis;
  • teriparatide

Summary

The advent of teriparatide [PTH(1-34)] and the full-length hormone [PTH(1-84)] provided an attractive therapeutic alternative to antiresorptive drugs like the bisphosphonates for individuals with advanced osteoporosis. This chapter reviews three key aspects of combination anabolic and antiresorptive therapy: antiresorptive therapy followed by anabolic therapy, concurrent use of anabolic and antiresorptive therapy, and antiresorptives after anabolic therapy. Postmenopausal women who had undergone antecedent estrogen therapy, and postmenopausal women with glucocorticoid-induced osteoporosis showed rapid and sustained increases in vertebral bone mineral density (BMD) with the use of teriparatide.